

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

11 October 2011

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

(1 page by email)

Dear Madam

BOARDROOM RADIO BROADCAST

Biotron Limited ('Biotron' or 'the Company') provides the opportunity to listen to an audio broadcast with the Company's Managing Director, Dr Michelle Miller, regarding the release of the positive results from the Company's Hepatitis C Phase 2A human trial.


Details of the webcast are as follows:

Title: Biotron's Hepatitis C drug candidate Phase 2a trial results
Speaker: Dr Michelle Miller, Managing Director
Live date: Tuesday, 11 October 2011 1:45pm AEST

Access this webcast at www.brr.com.au/event/87399

Access other Biotron webcasts at www.brr.com.au/asx/BIT

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn6259

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including influenza, Dengue and Hepatitis B.